首页> 外文OA文献 >Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

【2h】

Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

机译：使用血小板活化因子拮抗剂TCV-309治疗的严重SIRS和败血性休克患者的器官功能衰竭降低：一项前瞻性，多中心，双盲，II期随机试验。 TCV-309败血性休克研究组

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Poeze M.; Froon A.H.; Ramsay G.; Buurman W.A.; Greve J.W.M.;
展开▼
作者单位

展开▼
年度 2000
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
专利

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Case study of 8 Patients with multiple organ failure treated additionally with Cytosorbents haemadsorption as adjunctive therapy in septic shock and severe SIRS in cardiac failure [J] . Kogelmann K., Druener M., Jarczak D. Infection . 2015,第Suppla1期

机译：败血症性休克和严重SIRS合并心力衰竭的细胞吸附剂溶血吸收辅助治疗8例多器官功能衰竭的病例研究
3. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α Fragment antibody AZD9773 in Adult patients with severe sepsis and/or septic shock: Randomized, double-blind, placebo-controlled phase IIb Study [J] . BernardG.R., FrancoisB., MiraJ.-P., Critical care medicine . 2014,第3期

机译：评价两剂多克隆抗肿瘤坏死因子-α片段抗体AZD9773在患有严重脓毒症和/或脓毒性休克的成人患者中的疗效和安全性：随机，双盲，安慰剂对照IIb期研究
4. Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial [J] . Marx Gernot, Zacharowski Kai, Ichai Carole, Trials . 2021,第1期

机译：早期目标控制等离子体体积的功效和安全性用平衡的明胶溶液对具有严重脓毒症/脓毒症休克患者的平衡电解质溶液：研究方案，设计和理论的前瞻性，随机，控制，双盲，多中心，国际临床试验
5. Effect of the platelet-activating factor antagonist TCV-309 and the cyclo-oxygenase inhibitor ibuprofen on the haemodynamic changes in canine experimental endotoxic shock. [O] . S. Yamanaka, H. Iwao, T. Yukimura, 1993

机译：血小板活化因子拮抗剂TCV-309和环加氧酶抑制剂布洛芬对犬实验性内毒素性休克血流动力学变化的影响。
6. Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial. [O] . Froon A.H., Greve J.W.M., Buurman W.A., 1996

机译：血小板活化因子拮抗剂TCV-309治疗严重的全身性炎症反应综合征的患者：一项前瞻性，多中心，双盲，II期随机试验。

Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group

著录项

引文网络

相似文献

相关主题

期刊订阅